{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1290","value":"14400"},{"groupId":"OG001","spread":"12800","value":"27600"},{"groupId":"OG002","spread":"12700","value":"28600"},{"groupId":"OG003","spread":"6640","value":"29400"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"12"}],"units":"Participants"}],"title":"Week 1"},{"categories":[{"measurements":[{"groupId":"OG002","spread":"69600","value":"147000"},{"groupId":"OG003","spread":"66700","value":"139000"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"9"}],"units":"Participants"}],"title":"Week 20"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"12"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Participants received CAEL-101 500 mg/m\\^2 administered weekly as an IV infusion the first 4 weeks (DLT observation period), and thereafter received CAEL-101 at the RP3D (1000 mg/m\\^2) every other week until the end of study.","id":"OG000","title":"Part A: CAEL-101 500 mg/m^2"},{"description":"Participants received CAEL-101 750 mg/m\\^2 administered weekly as an IV infusion the first 4 weeks (DLT observation period), and thereafter received CAEL-101 at the RP3D (1000 mg/m\\^2) every other week until the end of study.","id":"OG001","title":"Part A: CAEL-101 750 mg/m^2"},{"description":"Participants received CAEL-101 1000 mg/m\\^2 administered weekly as an IV infusion the first 4 weeks, and then every other week until the end of study.","id":"OG002","title":"Part A: CAEL-101 1000 mg/m^2"},{"description":"Participants received CAEL-101 at the RP3D (1000 mg/m\\^2) administered weekly as an IV infusion for the first 4 weeks, and then every other week until end of study.","id":"OG003","title":"Part B: CAEL-101 1000 mg/m^2"}],"paramType":"MEAN","populationDescription":"The PKS included all participants who had at least 1 measurable plasma concentration. Number analyzed = participants evaluable at specified timepoint.","reportingStatus":"POSTED","timeFrame":"Predose through Week 1 and through Week 20","title":"Area Under Plasma Concentration-time Curve Over Dosing Interval (AUCtau) of CAEL-101","type":"SECONDARY","unitOfMeasure":"hours*µg/mL"}